SCHEMBL1773258

SCHEMBL1773258

CC1=Nc2ccccc2Oc2ccccc21

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 2/20 0.67
CYP1A2 P05177 2/20 0.60
CYP2D6 P10635 2/20 0.60
HRH4 Q9H3N8 5/20 0.50
HDAC3 O15379 1/20 0.42
HDAC1 Q13547 1/20 0.42
HDAC2 Q92769 1/20 0.42
KDM4E B2RXH2 4/20 0.41
TRPA1 O75762 1/20 0.39
ATM Q13315 1/20 0.39
DRD2 P14416 4/20 0.39
HRH2 P25021 3/20 0.39
HRH1 P35367 3/20 0.39
HTR2C P28335 3/20 0.39
DRD4 P21917 3/20 0.39
DRD3 P35462 3/20 0.39
ADRB2 P07550 2/20 0.39
CHRM2 P08172 2/20 0.39
CHRM4 P08173 2/20 0.39
HTR1A P08908 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3254394 0.83 MAPK1 (0.71) MAPK1CYP1A2CYP2D6HRH4KDM4E
SCHEMBL9434183 0.81 MAPK1 (1.00) MAPK1CYP1A2CYP2D6HRH4KDM4E
SCHEMBL8043895 0.81 MAPK1 (0.77) MAPK1CYP1A2CYP2D6HRH4KDM4E
SCHEMBL16330246 0.78 MAPK1 (0.45) MAPK1CYP1A2CYP2D6HRH4ATM
SCHEMBL14455165 0.77 MAPK1 (0.44) MAPK1CYP1A2CYP2D6KDM4EALDH1A1
SCHEMBL14455164 0.77 MAPK1 (0.44) MAPK1CYP1A2CYP2D6HRH4KDM4E
SCHEMBL30565769 0.77
SCHEMBL15963303 0.75 CYP1A2 (0.60) MAPK1CYP1A2CYP2D6HRH4HDAC3
SCHEMBL10059990 0.75 CYP1A2 (1.00) MAPK1CYP1A2CYP2D6HRH4HDAC3
SCHEMBL311434 0.75 CYP1A2 (0.60) MAPK1CYP1A2CYP2D6HRH4HDAC3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3542801-A1 PURIN DERIVATIVES FOR USE IN THE TREATMENT OF FAP-RELATED DISEASES Boehringer Ingelheim International GmbH (DE) 2019-09-25 EP claimed
US-20160136180-A1 PURIN DERIVATIVES FOR USE IN THE TREATMENT OF FAB-RELATED DISEASES BOEHRINGER INGELHEIM INT (DE) 2016-05-19 US claimed
US-20110112069-A1 PURIN DERIVATIVES FOR USE IN THE TREATMENT OF FAB-RELATED DISEASES BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-05-12 US claimed
US-20100144703-A1 XANTHINE DERIVATIVES, THE PREPARATION THEREOF AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2010-06-10 US claimed
EP-2190434-A2 PURIN DERIVATIVES FOR USE IN THE TREATMENT OF FAB-RELATED DISEASES Boehringer Ingelheim International GmbH (DE) 2010-06-02 EP claimed
EP-1562946-B1 NOVEL XANTHINE DERIVATIVES, THE PRODUCTION AND THE USE THEREOF IN THE FORM OF DRUGS BOEHRINGER INGELHEIM PHARMA (DE) 2010-05-26 EP claimed
US-7566707-B2 Imidazopyridazinone and imidazopyridone derivatives, the preparation thereof and their use as pharmaceutical compositions BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-07-28 US claimed
WO-2009024542-A2 PURIN DERIVATIVES FOR USE IN THE TREATMENT OF FAB-RELATED DISEASES BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-02-26 WO claimed
US-7482337-B2 Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2009-01-27 US claimed
EP-1641799-B1 IMIDAZO-PYRIDAZINONE DERIVATIVES AND IMIDAZO-PYRIDONE DERIVATIVES, PRODUCTION THEREOF, AND USE THEREOF AS MEDICAMENTS BOEHRINGER INGELHEIM INT (DE) 2008-03-12 EP claimed
US-20050026921-A1 New imidazopyridazinone and imidazopyridone derivatives, the preparation thereof and their use as pharmaceutical compositions BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2005-02-03 US claimed
US-20040138214-A1 Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2004-07-15 US claimed
EP-3542801-A1 PURIN DERIVATIVES FOR USE IN THE TREATMENT OF FAP-RELATED DISEASES Boehringer Ingelheim International GmbH (DE) 2019-09-25 EP disclosed
EP-2190434-B1 PURIN DERIVATIVES FOR USE IN THE TREATMENT OF FAP-RELATED DISEASES BOEHRINGER INGELHEIM INT (DE) 2019-04-17 EP disclosed
US-20170000749-A1 Methods for Treating Cognitive Disorders Using Inhibitors of Histone Deacetylase FMR LLC 2017-01-05 US disclosed
US-20160222026-A1 Dibenzo[B,F][1,4]oxazepin-11-yl-N-Hydroxybenzamides as HDAC Inhibitors FMR LLC 2016-08-04 US disclosed
US-5171636-A Photochromatic and thermochromatic spiro-oxazepin-oxazine compounds and the process for their preparation ENICHEM SYNTHESIS S.P.A. (IT) 1992-12-15 US disclosed
US-5110922-A Condensation, cyclization ENICHEM SYNTHESIS S.P.A. (IT) 1992-05-05 US disclosed
US-5055576-A Exposed to sunlight or electromagnetic radiation reversibly changes color; used in photography, solar filters, optical articles, decoration, toys and printing ENICHEM SYNTHESIS, S.P.A. (IT) 1991-10-08 US disclosed
EP-0432839-A2 Photochromatic and thermochromatic spiro-oxazepin-oxazine compounds and the process for their preparation ENICHEM SYNTHESIS S.p.A. (IT) 1991-06-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040138214-A1 Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions DPP4, DPP7, DPP3 MAPK1 2565/4885CYP1A2 208/4885CYP2D6 180/4885
US-20100144703-A1 XANTHINE DERIVATIVES, THE PREPARATION THEREOF AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS DPP4, DPP7, DPP3 MAPK1 3695/4885CYP1A2 201/4885CYP2D6 165/4885
US-20170000749-A1 Methods for Treating Cognitive Disorders Using Inhibitors of Histone Deacetylase HDAC5, KAT2A, HDAC1 MAPK1 3502/4885CYP1A2 3844/4885CYP2D6 4032/4885
US-20160222026-A1 Dibenzo[B,F][1,4]oxazepin-11-yl-N-Hydroxybenzamides as HDAC Inhibitors HDAC1, HDAC2, HDAC4 MAPK1 3423/4885CYP1A2 1799/4885CYP2D6 1008/4885
US-20160136180-A1 PURIN DERIVATIVES FOR USE IN THE TREATMENT OF FAB-RELATED DISEASES PNP, ENTPD5, NUDT14 MAPK1 4050/4885CYP1A2 4770/4885CYP2D6 4647/4885
US-20110112069-A1 PURIN DERIVATIVES FOR USE IN THE TREATMENT OF FAB-RELATED DISEASES PNP, PURB, NUDT14 MAPK1 3981/4885CYP1A2 4692/4885CYP2D6 4496/4885
US-20050026921-A1 New imidazopyridazinone and imidazopyridone derivatives, the preparation thereof and their use as pharmaceutical compositions DPP4, DPP3, DPP7 MAPK1 2447/4885CYP1A2 244/4885CYP2D6 14/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.